ClearPoint Neuro, Inc. (CLPT)

Clearpoint Neuro, Inc. (CLPT) stock has experienced several notable events in the past six months (August 2025 - February 2026). The company reported a Q3 2025 EPS miss and revenue below consensus estimates, leading to a stock decline. Clearpoint Neuro completed the acquisition of IRRAS, a neurocritical care company. The company received FDA 510(k) clearance to expand the compatibility of its ClearPoint PRISM Laser Therapy System with 1.5T MRI guidance. Clearpoint Neuro announced preliminary unaudited Q4 2025 revenue growth of approximately 20%. The company announced EU MDR Certification for its ClearPoint Navigation Software Version 3.0.2. In the past six months, CLPT's stock has trended up, but the share price has declined over the past year.

The provided information does not explicitly detail the demand seasonality for Clearpoint Neuro, Inc.'s products and services. The company's revenue streams suggest a potentially more stable demand profile. The reported strong preliminary revenue growth in Q4 2025 indicates consistent demand in these areas towards the end of the year. Without specific data on quarterly fluctuations or external factors influencing demand at different times of the year, it is not possible to definitively describe a seasonal pattern.

Clearpoint Neuro, Inc. (CLPT) is a medical device company specializing in precision navigation technologies for minimally invasive neurological procedures. The company develops and commercializes platforms that enable MRI-guided surgical procedures in the brain and spine. Its major products and services include the ClearPoint System, ClearPoint Prism Neuro Laser Therapy System, SmartFrame OR, ClearPoint Maestro Brain Model, ClearPoint Array Platform, ClearPoint Disposables and Software, and Pre-clinical Development Services. The company generates revenue through a "razor-and-blade" model, involving disposable products, therapeutic delivery services, and capital equipment installations.

Clearpoint Neuro, Inc. has a global reach, serving healthcare and research centers across North America, Europe, Asia, and South America. The company has expanded its operational footprint with a new lease agreement in San Diego, California, for office, research and development, and laboratory purposes, with phased occupancy beginning in June 2025 and continuing into 2026. The company also provides neurosurgery platforms and services primarily in the United States and Europe.

Clearpoint Neuro's brand reputation is strengthened by regulatory achievements, strategic expansion, strong revenue growth, and partnerships. The company's receipt of EU MDR Certification for its navigation software and FDA 510(k) clearance for its PRISM Laser Therapy System with 1.5T MRI guidance are significant regulatory milestones. The acquisition of IRRAS and the establishment of the ClearPoint Advanced Laboratories (CAL) preclinical CRO facility highlight the company's commitment to growth and innovation. The preliminary 20% revenue growth reported for Q4 2025 indicates strong market acceptance. Clearpoint Neuro maintains strategic partnerships with leading organizations, further solidifying its reputation.

Clearpoint Neuro, Inc. (CLPT) has a diverse ownership structure. Institutional shareholders hold 35.09% of the company's stock. Individual owners (insiders) hold 26.36% of the stock. Retail investors collectively hold 38.55% of Clearpoint Neuro shares.